T. Kalincik Et Al. , "Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS," 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS , vol.25, Stockholm, Sweden, pp.912-914, 2019
Kalincik, T. Et Al. 2019. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS. 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS , (Stockholm, Sweden), 912-914.
Kalincik, T., Malpas, C. B., Sharmin, S., Roos, I., Patti, F., Butzkueven, H., ... Alroughani, R.(2019). Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS . 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS (pp.912-914). Stockholm, Sweden
Kalincik, T. Et Al. "Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS," 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 2019
Kalincik, T. Et Al. "Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS." 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS , Stockholm, Sweden, pp.912-914, 2019
Kalincik, T. Et Al. (2019) . "Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS." 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS , Stockholm, Sweden, pp.912-914.
@conferencepaper{conferencepaper, author={T. Kalincik Et Al. }, title={Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS}, congress name={35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS}, city={Stockholm}, country={Sweden}, year={2019}, pages={912-914} }